0001193125-24-149802.txt : 20240530 0001193125-24-149802.hdr.sgml : 20240530 20240530071801 ACCESSION NUMBER: 0001193125-24-149802 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240528 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240530 DATE AS OF CHANGE: 20240530 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Monte Rosa Therapeutics, Inc. CENTRAL INDEX KEY: 0001826457 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40522 FILM NUMBER: 241000706 BUSINESS ADDRESS: STREET 1: 321 HARRISON AVENUE STREET 2: SUITE 900 CITY: BOSTON STATE: MA ZIP: 02118 BUSINESS PHONE: 617-949-2643 MAIL ADDRESS: STREET 1: 321 HARRISON AVENUE STREET 2: SUITE 900 CITY: BOSTON STATE: MA ZIP: 02118 8-K 1 d836893d8k.htm 8-K 8-K
false 0001826457 0001826457 2024-05-28 2024-05-28

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 28, 2024

 

 

MONTE ROSA THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-40522   84-3766197

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(I.R.S. Employer

Identification No.)

321 Harrison Avenue, Suite 900

Boston, MA 02118

(Address of principal executive offices, including zip code)

(617) 949-2643

(Registrant’s telephone number, including area code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading
Symbol(s)

  

Name of each exchange

on which registered

Common Stock, $0.0001 par value per share   GLUE   The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On May 28, 2024, the Compensation, Nomination and Corporate Governance Committee of Board of Directors of Monte Rosa Therapeutics, Inc. (the “Company”) promoted Jennifer Champoux, the Company’s Chief People and Operations Officer, to serve as the Company’s Chief Operating Officer, effective as of May 28, 2024 (the “Effective Date”).

Ms. Champoux, age 52, has served as the Company’s Chief People and Operations Officer since March 2023, and was previously the Company’s Senior Vice President of Operations from March 2021 to March 2023. Prior to joining the Company, from June 2017 to March 2021, Ms. Champoux was with H3 Biomedicine Inc., leading operations, communications, and finance operations teams. Earlier, Ms. Champoux was with Novartis Institutes from Biomedical Research, leading operations for the Discovery Chemistry group in Cambridge. She previously worked in various roles at Merck and Array BioPharma. Ms. Champoux holds an M.S. in chemistry from Indiana University and brings over 15 years of diverse operations experience, including site operations, strategic planning, finance, communications, and culture and employee engagement.

There are no arrangements or understandings between Ms. Champoux or any other person pursuant to which Ms. Champoux was promoted. There are no family relationships between Ms. Champoux and any other director, executive officer or nominees thereof of the Company. There are no related party transactions between the Company and Ms. Champoux that would require disclosure under Item 404(a) of Regulation S-K under the Exchange Act.

Item 7.01. Regulation FD Disclosure.

On May 30, 2024, the Company issued a press release announcing Ms. Champoux’s promotion and the promotions of two other individuals. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly provided by specific reference in such filing. The Company undertakes no obligation to update, supplement or amend the material attached hereto as Exhibit 99.1.

 

Item 9.01.

Financial Statements and Exhibits

(d) Exhibits

 

99.1    Press Release issued by Monte Rosa Therapeutics, Inc. dated May 30, 2024.
104    Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    Monte Rosa Therapeutics, Inc.
Date: May 30, 2024     By:  

/s/ Markus Warmuth

      Markus Warmuth
      President and Chief Executive Officer
 EX-99.1 2 d836893dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO

Monte Rosa Therapeutics Announces Leadership Team Promotions

BOSTON, Mass., May 30, 2024 – Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced three leadership team promotions effective immediately: Sharon Townson, Ph.D., to Chief Scientific Officer; Phil Nickson, Ph.D., J.D., to Chief Business and Legal Officer; and Jennifer Champoux to Chief Operating Officer.

“I am very pleased to announce the well-deserved promotions of Sharon, Phil and Jennifer to expanded roles on our leadership team,” said Markus Warmuth, M.D., Chief Executive Officer of Monte Rosa Therapeutics. “Each has played a critical role in advancing our pipeline programs, enhancing our QuEEN™ drug discovery engine, developing relationships with premier biopharma companies, and building an outstanding organization. I look forward to continued work and collaboration with this talented group as we advance our pipeline programs targeting cancers and immune-related diseases and further leverage the potential of our AI/ML-driven discovery engine.”

Sharon Townson, Ph.D., promoted to Chief Scientific Officer, joined Monte Rosa as Chief Technology Officer and brings expertise in molecular glues and targeted protein degradation technology platforms. She joined the Company from Kymera Therapeutics, where she served as Executive Director of Platform Biology. Previously, she was on the leadership team of Warp Drive Bio and was responsible for developing their novel molecular glue approach to target KRAS. Sharon began her career at Pfizer as a structural biologist and holds a Ph.D. in structural biology and biochemistry from the University of Manchester Institute of Technology.

Phil Nickson, Ph.D., J.D., promoted to Chief Business and Legal Officer, joined the Company as General Counsel and has provided general legal support, including work on intellectual property matters and external business transactions. Phil joined Monte Rosa with over 15 years of life sciences legal experience. Previously, he was with Momenta Pharmaceuticals for over 10 years, through the company’s acquisition by Johnson and Johnson. Phil began his legal career with Fish and Richardson in Boston. He holds a J.D. from Suffolk University and a Ph.D. from the University of Manchester.

Jennifer Champoux, promoted to Chief Operating Officer, joined Monte Rosa as Vice President of Operations, leading overall corporate operations and Human Resources. Jen brings over 15 years of diverse operations experience, including site operations, strategic planning, finance, communications, and culture and employee engagement. Previously, she was with H3 Biomedicine, leading operations, communications, and finance operations teams. Earlier, Jen was with Novartis Institutes for Biomedical Research, leading operations for the Discovery Chemistry group in Cambridge. She previously worked in various roles at Merck and Array BioPharma. Jen holds an M.S. in chemistry from Indiana University.

About Monte Rosa

Monte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecular glue degrader (MGD) medicines for patients living with serious diseases in the areas of oncology, autoimmune and inflammatory diseases, and more. MGDs are small molecule protein degraders that have the potential to treat many diseases that other modalities, including other degraders, cannot. Monte Rosa’s QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates) discovery engine combines AI-guided

LOGO

 

chemistry, diverse chemical libraries, structural biology and proteomics to identify degradable protein targets and rationally design MGDs with unprecedented selectivity. The QuEEN discovery engine enables access to a wide-ranging and differentiated target space of well-validated biology across multiple therapeutic areas. Monte Rosa has developed the industry’s leading pipeline of MGDs, which spans oncology, autoimmune and inflammatory disease and beyond, and has a strategic collaboration with Roche to discover and develop MGDs against targets in cancer and neurological diseases previously considered impossible to drug. For more information, visit www.monterosatx.com.

Investors

Andrew Funderburk

ir@monterosatx.com

Media

Cory Tromblee, Scient PR

media@monterosatx.com

###

EX-101.SCH 3 glue-20240528.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 glue-20240528_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period EX-101.PRE 5 glue-20240528_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 g836893dsp5.jpg GRAPHIC begin 644 g836893dsp5.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_VP!# (! 0(! 0(" @(" @(" P4# P,# M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_ MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P, M# P,# P,# P,# P,# P,# P,# P,# S_P 1" ] -\# 2( A$! Q$!_\0 M'P 04! 0$! 0$ $" P0%!@<("0H+_\0 M1 @$# P($ P4% M! 0 %] 0(# 01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D* M%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#]^*POB7\0 M-(^%?P^UGQ+KU[%I^BZ#9R7]]<2'Y8H8U+,??@<#N<"MP]*_)S_@Y _;D2QT MK3/@5X=OC]HOO*U;Q687^Y"#FVM&]W8>:P]$C_O5Z^0Y15S/'0P=/KN^RZL\ MC/00?0U_),X\Q2" M01@C'!K]X_\ @@+^W!OTKQ'X4HX:A3Q^#C:,$H27EM%_H_D?G?A[Q14Q%>I@L7*\I-RB_P 6 MOU1]K?%KXFZ)\&?AGKOBOQ'>1V&A^';*2_O9W/\ JXXU+''J3C 'S6_@7XI74>D:A8RRDP:%:JVVPD Z#RC^;U]$YNKF410V\:C+.[M@*H )))P *XCN+=%Z'\,O#%SK?B36=+\/Z M-9;3<7^HW26MM!N8*NZ1R%7+$ 9/4BC=V0&M17E0_;L^"!'_ "6/X6?^%58_ M_':] \(^.=%^(&AP:GH.KZ9KFF7.?)O-/NDNK>7'7;(A*G\ZN5.4?B5@-6BB MBH ****+@%%%% 'F/[87[46A_L=?LY^)_B#KQ!M]#M2UM;;@&O[I_E@MU_VG MD*CV&3T%?S(_%;XHZW\;OB9KWC#Q)=->Z]XDOI-0OICT,CG.U?15&%4=E4#M M7W/_ ,' G[=7_#0'[047PMT"[+^$_AM.RW[1MF._U !U)/ 'O7[G_LI^ ]%_P""*'_!+?5O''BZUB/C?6(%U34K M=B!+=ZC*NVSTT=\1@@-Z'SFZ5\1_\$$OV#O^&FOVE/\ A8&O6?G^#/AI*ERJ M2IF/4-5/S018/#"(8E8>OECO2_\ !>W]NS_AI']I-?A]X?O?.\'?#2>2&5XF MS'J&K$;9Y>.&$0_=+[^:>]1Q+.6=9K3R&D_W<+3JO\H_UU:[,KAZE')\MGG= M5?O)7C37YR_KIZGQ'\1?B#K'Q:\?ZUXH\07CZAKOB&]EU"_N7ZRS2,68CT S M@#L !VK)@MY+N9(H8Y)II6$<<<:EGEA$"XD/^T8O>OL\XS.AE.7RQ,M(P M6B\]DCX_*L!6S3'QP\?BF]7V75GV]^S!X7\)?\$-?^";">*/'T,Q\1:S-!?: M_#9A6N[V_GPL5E$"0#Y,>1UQ\DK=Z^X_ ?CS2OB;X,TGQ#H=W'J&CZY:17UE MKMNK-N4UVB]ON_+3H?M&3\3X6GFG]BT4E2B MN6+[R6_W_F?K%7C/_!1-?\%%/^3!/C7_V( M^L?^D4M?GU#^+'U7YGZ&]C\7?^#:CXXZM^R3^TGX8\+^("EKX$_:5TNX;0IL MXB_M73II(@O3 D8"2,@==\-?JS_P6C_;/;]A[_@G]XS\1Z?.8_%6O1#PYX;1 M.96O[H,BN@'),:>9)QWC'K7Y??"+]G'5?B1_P;B_#WXI^#RT7Q#_ &??%>H^ M-M$N(\^8L,-\S748QVV*LA'?R!ZU[)HGQ^L?^"\G_!4/X$VFDQF;X4_!?PY; M^/O$L!!,+:U,$86C _>\N811]\B.?'!KZ7'T(5L6\5)>[!OG_P"W=OOT1"VL M>5_\&X6GVG[#'[4'[3R?$:\LO#T?PY\+6C>(KN5ODLO*GD>7<<99ES@CJ6& M"37U=;_\'#NM^.O#>J^-? /[*WQF\:_"31Y95G\71>7;HT41_>2I#L;(49)& M_P"7'S;<''P!^TCX8UOQ=\4_^"GEMH*S2W%M?V%]>)""7>RAUP27' ZJJ+O/ M^RA]*_77_@EA^T;\+T_X)3_#'7++7_#FG>%?"WA&WM=;,UU&B:5-!%MNTG7/ MRMY@');2&6.RO-$N1$\LBW*OD H%Y"DY#*RD@@UQ'Q0_ MX.')?AIH\?C7_AFOXSW?P3GN$BM_'T\"6EO>Q.VU)XH'7/EN?N%W7?D8Y(%? MCYXGT2?4/^":'CKQ!96D]MX!\4?'B'_A'XI%*Q2(EA>^9L7T$F!6>(R_"X><(< MO-S2:W>BT[=5>Q5W8_/;_@NK_P %1?%GQR^&_P /M.\#^%OB7X9^&VI^(K2_ ML?%L5U]ETOXAVS6Z3);1!"')#-RC\!HR"#BOMSQW_P %OM)^!'[/-EXJ^)OP MA^)G@'QKX@UN30_#/P_O(8YM>\1,B1'[1$JG:L!:4)N/\0P 20*_-K]MP;/^ M"&G[!;'[B>(URQZ#F?O^%>R_\%O1JT/_ 67_9O\2VOQ!L?A]HE]I2Z7HWC* M6TAU.P\/Z@L\^]G1SY6[]];YW$;1(K_PY'1]2H3C2H..B=376[Y?\_\ AA7> MZ/J/0/\ @NW<_#?XG^%]$^/W[/\ \3/@'I'C:Z%GH_B#698KS3C,V $G9%4P M]1G.2N>>0?^)A;5\:?\%:OV9?%FB?LY MZ9I7[27[;B:OX1\0:M;_ -EZ;8?#6WN[^[NU5_*EABM91,P4,P+*=OS@'[P% M?5/_ 6QT.7PO_P0@\9:9-=7-]-IWA_1+5[FXA,,URR75FID="249L9*DD@D MC/%>;&A1C7H5*/66MKVZ;+[B3]F3PEH;ZK<;+IK^WMKY9;6.&*W()$DQFFGMTP_\ @C[X7^*'PZ'B=?C)JOA.W\1+;RZJ\UEJDH3?-:I ?E0R*&"8Z-M' M0FO"?BG_ ,*Z^)'_ ;[:5?_ P\&VWAS7O"'CO3HOBQ:VQDDN[J58+F*WNY MG3MQY?\ M>9M_P!JO^,V\0>&S\-)O [1(/M$?DR0M9&-;,)G_ %G(B\K&[=\N M,U^-'[('PF^&GC;_ ()T_L_>&?BKX[\8_![QWXC^(&KZO\)_%EII[36-D/,M M8G$TI*I'&;J(.&WH00'#8)SYU#"8>LO:2@XJ,K6U=U9_/2VMNG0>I^D-O_P7 MAOOA)\1_"NE_M ?L]?$KX"^'_&5ZFGZ9XCU6YAO=/6=R JSE%4Q]03U*C)*X M!([_ /;*_P""QFC?L[_M'V_P8^'WPZ\9?&[XN-:+?WGA_P -E(TTN!E#JT\[ M9"G85; 4@*ZEB-PS\9_MM_%_]I[_ ();^'O!.J_&CQY\'?VH?AAK&O0V2:+K M?A^"/5W8HQ$\2[3E@@<"0%P&90PP]=58?M-?$K]K+_@JY\7O 7[/\?P7^ VJ M^#;=8-<\7:YX8BO_ !+XFV^4K+@[=R*P7Y#]U40ECE0#ZA3=JJBN6S>DGRZ. MVMUS?(+GU9^P_P#\%=])_:G_ &@-8^$'C3X>>+_@S\7M(LSJ/_",^(2DGVVV M #&2"9 Y"L&QM&5.5+ ''V'7X:_L^3^)[3_ (.8_ &F>,/BYIOQH\3Z-H=W M9ZEKVG:9!I]M;2?V==O]B6.%F3,0<$G.THI]>O MKK]XT?(E[_P0J_9DU*]FN)_ -W+-<2M-([Z_?EG=CEF)\[)))))/K49_X(/? MLO$?\D]N/_![?_\ QZOL"BNA<19JE98F?_@4O\SR7D&6-W>'A_X"O\CS[X,? MLQ^#/V;OA G@?P%HZ>&/#Z";;%:2,T@DESOF,CDNTA/.YB3P.P K^:W]KS]G M#7/V2?VC?%/@#Q#OEO\ 0[QO*NV!_P")E;2?/#<@GKYB$$^C;AU!K^I(C(K\ MZO\ @X-_8+/QW^!-M\5/#EEYOBKX[0-F0?[)E]:^GX! MXB>"S1QQ+]VMHV]^;HV_5V?WGS/'7#WUS+E/#KWJ6J2[=5;Y71^+/PI^%^M_ M&SXEZ%X1\.6C7VN^)+V/3[*$#[TCG&6]%499CV52>U?TQ_LF?LD>'?V4OV8= M ^&NDJ7LM-L3#?7*GRY=0N) 3<7#,,,&=V8@YR!M / K\Z?^#<;]A4Q?;_CU MXAMB%N$ETGPDD@^]&?EN;P?7'E*?02>HK];E&T8%=GB5Q#];QOU"B_W=+?SE M_P #;UN$[(W>J7=O<@PR;$#H0H5B68,"HY%> MJTUT$@Y^M>5%V=SU#\W/A/\ MO\ P?\ V$?@QX=^#FE_LS_M,>&?#'BN\NM* MT;1=4\,"=]9N+A7EGMXS+=,\C,GF$KG[H/I6I^PAXB^#/[!OAGXBW'@;]FS] MH#X3Z)'HMSXIU[5/$VANL%Q%IT#R"!)9;F0^859_+C&%)+9(KO/^"IW_ "=C M^Q9_V5=O_39=5[=_P48BW?L _&\ [<^!-: )Z#_0IJ].OO/HQ:' M/_LE?LC_ =L]"O#=Y9ZM\?]+M]9UN6_N9)OM\-THN%62!W:-"?-^9 M5&.2.17DGC/_ (-T/V3/&GCJ?7'^'EYIJW\$VL/@7P9=I>Z-I&ESRZ=#92JCH&'DLI M;(=B=Q.2Q)R>:]+^.7P"\+_M&_!/7?AYXML9-0\*>([+^S[^U2X>!I8>/E$B M$,OW1R#FOE;XT?%[]IG]@'P/_P +/^(GBCX=?%GX<:+)$_C#3]'\-3:'J>AV M3R*DE[9N;B5;@0[@S1R!69 Q!!%0Z_\ M??'WXW?MW?%;X._")?AOI^B^#]) MT'6;?Q5X@L[BZBLH+VU>1H_(BE0W$LKX*?-&B)&^2Q917/[.K)B_ _6/!=MJWPV\.JHTS3;NYF>2Q96=EDCGW"5 M7!D?Y@^<,1T.*Y'PK_P1C_9O\)?LY:Q\*(OAS:7G@?6]3.LSV-]>W%S)%>^6 ML7GPS.YDB?8H&48<9]36#!X]_:@_: ^)^O>$_"EWX3^&>A?#M;72M5\8ZYX6 MN+V7QEJIMTDN)--LVFC2*Q1FVB1Y)"S9 ^Z37G_C?_@H]\6?V??A/^TMX3\< MP^"[WXM? SPC%XPT?7--LYH]'\16%PDGDRRVK.7AECDB=)(Q(0>"IQ5TXXB? MNPG=W3M?N]_Q]0/0/V"+O5/$&CL)-,GU[5KG5$TQ MU.5:&.9RBLIZ':2I&1@\U]#?M)?LV^$?VM?@IK/P]\=Z?+JWA77UC6^M4N9+ M=I@DBRK^\C(8?.BG@]J^:/ /B+]K[]J#X3:-\1O#WB+X5?"RTUO3K?4='\)Z MUX=N-5N+J)XU=6O[I)T\AI<[O+A1_*5U!9V!K.L?^"N>KZE^RS:WD7@&-?C[ M=>.&^%?_ @SW^+2+Q*F6=FN<9^PK /M/F8SY>!]XYHG#$3DI.7-):;ZH1]= M?!/X->'_ -GGX3>'_!'A2T?3_#GA>QCT[3K9YGF:"%!A5+N2S8]22:\E^'G_ M 2V^!_PM^*GQ \7:-X,A@OOBG!/;>*;&6YEFTO5XYI/-D#V;L81ERQ&%&-[ M8QN->5?&'QM^UM^QU\,-0^*7B7Q)\+OBMX>\,6[:IXH\)Z/X;N-'N[>P3Y[E M]/NVN)/-DAC#,%F0>8$(RI(KO_V?/VTM2^.O[>'C#P18/IMS\/K'X=^'?&>A MW:0,MW<-J4EUDNQ;!3RXHBH"@@DY)K+DJQC*I"5UU:?9K_,9YA!_P;A_LD0> M-1J__"O=0>V6X^TKH[^(+UM+#>GD^9C;[9QCCI7NOQU_96^ _P"TQX-M/@=X MR\-^$M7L-*TU-2T_PTFV"?2+5#Y"7%NL15X%!.P,I /(YY%9'[7W[4'BKX*_ MM1?L\^"?#ZZ1_9_Q7US5=+U62\MVEDA2WTV2XB:(AEVGS%&[(.5R!CK7R'X3 M\!?M+R_\%A?&]K!\1?A#'X[7X5:7)=:DW@Z\;3I+ ZGP;'>?LV?\$H?V+_AQ^V/J?ASP]H5_XB^*'PTM M++6IM,U_5+[4X=#BN&+6LR+,3 Q)3('S;2 < @5[!^UG_P $6_V>?VTOB>?& MOC3P;M/']F,A8[@\JQ)&I'RE^2:OZ+I M?[;_ (P\ Q^-_P#A)_@GX:UNYA%_;_#NX\/W5S!$I72Z5XU*-XBCG@G1HY(Y%# M)(K#!4@\$$'!%2T4 9?@WP5I/P\\+6&B:'IMCI&CZ7"MO9V5G"L,%K$HPJ(B M\*!Z"M2BBAMMW8)65D%%%% !1110!\5?\%3_ /D[+]BS@_\ )5V[=/\ B675 M>W_\%'.?^"?WQPZ_\B)K?3_KQFKV"XL(+R6)Y88I6@;?&70,8VZ9&>A^E/N+ M=+N!XI$5XY 5964$,#U!!X-='M[JFK?!^.MP/*/V"%!_89^"O'_,BZ'VZ?\ M$O@K\F8/@=I7B'P'H_Q1\7^%=5\7_#'X;?'_ ,?V?C>RTYKH75CINH3K$-1" MVS+,T=O-%&TFPYV,3@@&OV]M[=+2!8HT5(T&U548"@= !V%1VVG064;K#%%" MKL781H%#,>I('4FM*.,=*4I)?$_\U^3 _*#]H/PC^PU>?#NVT?X.^$?#WQZ^ M(WC)XK'0/!^B^-=6OA>M*ZJ\EZ8[EQ;6T:%GD>4 +C!-?2G[$NBQ^'/^"JO M[5&G0V\5K#8^'_ MM'%"S-'$J:=1_$#X:_&7]I#XU67[6'QK\3^ -=\*^++NR\/\ @JX\977A M/1XM 14^Q7ENL+P_;3.I+-)O<[OEPN *^;_%5EX&CN/V[)?AKH.NZ#\/KWX& MV1N5 P4!A7[A>)/ &A>,;JVFU?1=) MU6:T.8'O+..=H#U^4NI*_A7SI_P6;TV&'_@E?^T%.L42S/X'OXVD" .RB/@$ MXS@>E=.!QR]LJ:6[BK7T6JV^X5M#E/V>/^"M_P $_"G[,/AR/XE^,M'^&/C' MPYH5E!KOACQ!)]EU.VF2!!F"$C?N_'.7XDZEX,2&>#6SX1DL%TQ;KR8F683B)$NC&I#[,_2OU M3^"?@+0_$OP6^'E_J.C:5?W]EX>T_P"S7-S9QRS6_P#HT9^1V4E>?0UZ-@XZ MGZUC#%*A4H:Y>2X2.":!;EGMX\M^\:95"*&SR,5Z;X4\=^'/^"=?_!2^*_\ BZ% MX=UBXU&PT;2;'4+O/GW5O91133YY.YU4,?Q-6O$7AK3O%NEO8ZK866IV,G+V M]W;I/$^.F58$'\JSGB[KEGS-:[N_W?UJ!^='[1O[8_A#]JW_ (*@?LC6WP[N MSXL\+>&_%.M+>>*+%3)H\M\^D2[;.WG^[/(L:L[F,LJ;D!;?M.?MCZ/X"BCUS6K_P"' M'@/Q%H,"-M359+.[GOHXE)X/FK%M&>[K7U9X<_X+:?LZ:I\&O^$EUGQ_I?AS M688!_:'A#4 \7B6RO /GLO[/($[S!P4 5"&."#@YKZN@TFWM;@RQPPI*RA"Z MQJ&*CH,@9P.WI5"?X?Z'=>)$UF71M)DUB/ 2_:SB-RF.F)-NX?G3GB8U8J,T M[+;7R2[>0'PE^T5^TK:?$S]GSX0WG[57P(T[2OA9\1_M=QXBN;TSW;_#N[5] MVE-=;$$EL983AY@R^3(=A.#FOGW]HWQKX6_9MC\/_P##!_QC\5_$'XIZG=LB M?#[3O%4WC/0KNP\B5IIYXIGE6U\H!2C^8A+;5PV:_8.XM8[RU>&9%EBD4JZ. M-RN#P00>"*R_"_P_T+P29CHNC:3I'V@YE^PV<=OYI_VMBC/XTZ>.4&E;3^6_ &N_-,#__9 end XML 8 R1.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Document and Entity Information
May 28, 2024
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001826457
Document Type 8-K
Document Period End Date May 28, 2024
Entity Registrant Name MONTE ROSA THERAPEUTICS, INC.
Entity Incorporation State Country Code DE
Entity File Number 001-40522
Entity Tax Identification Number 84-3766197
Entity Address, Address Line One 321 Harrison Avenue
Entity Address, Address Line Two Suite 900
Entity Address, City or Town Boston
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02118
City Area Code (617)
Local Phone Number 949-2643
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, $0.0001 par value per share
Trading Symbol GLUE
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period false
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.1.u2 html 1 24 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://monterosatx.com//20240528/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d836893d8k.htm glue-20240528.xsd glue-20240528_lab.xml glue-20240528_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "d836893d8k.htm": { "nsprefix": "glue", "nsuri": "http://monterosatx.com/20240528", "dts": { "inline": { "local": [ "d836893d8k.htm" ] }, "schema": { "local": [ "glue-20240528.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd" ] }, "labelLink": { "local": [ "glue-20240528_lab.xml" ] }, "presentationLink": { "local": [ "glue-20240528_pre.xml" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 25, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "report": { "R1": { "role": "http://monterosatx.com//20240528/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "duration_2024-05-28_to_2024-05-28", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d836893d8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "duration_2024-05-28_to_2024-05-28", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d836893d8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://monterosatx.com//20240528/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://monterosatx.com//20240528/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://monterosatx.com//20240528/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://monterosatx.com//20240528/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://monterosatx.com//20240528/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://monterosatx.com//20240528/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://monterosatx.com//20240528/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://monterosatx.com//20240528/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://monterosatx.com//20240528/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://monterosatx.com//20240528/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://monterosatx.com//20240528/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://monterosatx.com//20240528/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r7" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://monterosatx.com//20240528/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://monterosatx.com//20240528/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://monterosatx.com//20240528/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://monterosatx.com//20240528/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://monterosatx.com//20240528/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://monterosatx.com//20240528/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://monterosatx.com//20240528/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://monterosatx.com//20240528/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security 12b Title", "terseLabel": "Security 12b Title", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://monterosatx.com//20240528/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "terseLabel": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://monterosatx.com//20240528/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "terseLabel": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://monterosatx.com//20240528/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "terseLabel": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://monterosatx.com//20240528/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "terseLabel": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 16 0001193125-24-149802-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-24-149802-xbrl.zip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end XML 18 d836893d8k_htm.xml IDEA: XBRL DOCUMENT 0001826457 2024-05-28 2024-05-28 false 0001826457 8-K 2024-05-28 MONTE ROSA THERAPEUTICS, INC. DE 001-40522 84-3766197 321 Harrison Avenue Suite 900 Boston MA 02118 (617) 949-2643 false false false false Common Stock, $0.0001 par value per share GLUE NASDAQ true false